Evernorth Health Services has introduced Evernorth Oncology Benefit Services, which will be available to eligible commercial plan sponsors in 2025, with plans to expand over time.
Researchers have identified sleep apnea as a common comorbidity among patients with cardiodiabesity.
The clinical efficacy of a drug must always take priority over any other considerations when developing formularies.
Regulatory pressures and technological advancements are changing utilization management as we know it—here’s what plan sponsors should know.
84% of patients getting care with Evernorth Behavioral Care Group have experienced a clinically significant reduction in their depression or anxiety symptoms.
Digital tools and AI-enabled processes can help evolve prior authorizations to deliver the best outcomes for patients, providers and payers.